Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Vietnam Drug Administration Rejects Changes In Price Cap Rules

This article was originally published in PharmAsia News

Executive Summary

The Drug Administration of Vietnam told drug makers it has rejected their suggestions and will maintain current procedures controlling the prices of drugs. The companies had wanted the Health Ministry to drop its requirement that they present material invoices when they request price increases, and instead to base the price caps on marketing prices in the exporting country. The firms were told Vietnam intends to retain current policy of basing prices on cost, insurance and import transportation costs, the central factor drug makers want changed. Prices also are based on transportation and management costs, and on profit margins. (Click here for more

You may also be interested in...



GSK Begins ‘New Chapter’ in India As It Offloads Nutrition Brands

GSK commits to investing behind OTC and oral health brands in India after offloading nutrition assets to Unilever.

Interview: iTeos Attracts Investors By Targeting TIGIT

The Belgian biotech has managed to attract considerable sums from venture capitalists over the past couple of years amid hopes that its two next-generation immunotherapies will be best-in-class agents.

Cipla Claims Success With Advair Trial

Cipla is celebrating an “important milestone” for the company after the successful completion of a Phase III clinical trial comparing its proposed Advair generic with GSK’s brand in the US. Management has cautioned that approval will be a way off yet, however.

UsernamePublicRestriction

Register

SC069831

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel